MK6482-011

About this trial

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Patient Profile

For Patients with Advanced Renal Cell Carcinoma (RCC) with clear cell component after prior therapy

Where’s this trial being run?

Tallaght University Hospital, Mater Misericordiae University Hospital, and Mater Private Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	MK6482-011
Number:	21-17
Full Title:	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Principal Investigator:	Prof. Ray McDermott
Type:	Industry Sponsored
Sponsor:	Merck Sharp & Dohme LLC
Recruitment Started:	Global: 25-Feb-2021 Ireland: 09-Dec-2021

Global Recruitment Target:
Ireland Recruitment Target:	8